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Introduction 
One of the most prevalent health issues that continue to 
affect a growing number of Americans in the twenty-first 
century is obesity. In just the past 50 years, the number of 
overweight and obese individuals has risen to 64% of adults 
and 25 million children in the U.S. (Ogden et al., 2008). 
Obesity not only causes lifestyle limitations but other health 
problems as well, including coronary heart disease, type II 
diabetes, cancer, hypertension, dyslipidemia, stroke, liver 
disease, gallbladder disease, sleep apnea, respiratory 
problems, osteoarthritis, and reproductive problems in 
women (Pi-Sunyer, 2002; Ogden et al., 2008). Therefore, the 
exploration of different means to combat obesity has been 
brought to the forefront of medicine over the past decade. 
A number of studies have looked at treating leptin 
deficiency, one of the main causes of obesity, through gene 
therapy with recombinant adenoviruses, direct administration 
of leptin either intracerebroventricularly or peripherally, and 
using skin explants from transgenic mice over-expressing 
leptin (Chen et al., 1996; Christensen et al.,1999; Muzzin et 
al., 1996; Larcher et al., 2001). Unfortunately, each of these 
approaches has a number of limitations, rendering the 
treatment either ineffective or unable to produce long-lasting 
results. In 2001, however, it was found, while examining the 
effects of ciliary neurotrophic factor in humans to treat motor 
neuron disease, that there was a substantial weight loss in 
test subjects over the course of treatment (Lambert et al., 
2001). The effectiveness of CNTF in weight loss can be 
attributed to its binding to a different receptor that activates a 
similar JAK-STAT signaling pathway to moderate food intake 
and perception of hunger, just as leptin does (Gloaguen et 
al., 1997; Kelly et al., 2004; Lambert et al., 2001).  
An additional advantage of CNTF in treating 
obesity is that it appears not only to be effective in ob/ob 
mice, where leptin hormone protein is nonfunctional, but also 
in db/db mice, which are lacking a functional leptin receptor 
(Gloaguen et al., 1997; Kelly et al., 2004; Lambert et al., 
2001). This means CNTF could actually lead to a universal 
treatment for obesity. It was also noted by Lambert et al. 
(2001) that unlike dieting and other treatments for obesity, 
treatment with CNTF resets the “hypothalamic weight 
setpoint” – after stopping the administration of CNTF there is 
no immediate rebound weight gain due to increased 
appetite. Given the initial potential CNTF treatment shows 
for reversing the obesity phenotype, it seems pertinent to 
look at several different aspects of CNTF administration and 
its effect on gene expression.  
 
Aim of the Study 
 
To determine the effects of CNTF administration and detect 
related changes in gene expression, the following will be 
examined: 
1. The maximum effective dose of CNTF, where no visible 
adverse effects are apparent and the longevity of 
weight loss effects is maximized between additional  
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CNTF treatments. 
2. The potential transcriptional up-regulation of genes in 
various brain regions related to increased levels of 
CNTF.  
 
Experimental Proposal 
 
Maximum Effective Dose of CNFT in ob/ob Mice 
In the development of drug therapies, it is necessary to 
balance both the associated positive and negative effects. 
While CNTF appears to be successful in reducing body 
weight, it has also been shown that high levels of CNTF can 
induce fever and inflammatory response pathways (Kelly et 
al., 2004). Therefore, the first goal of this study is to examine 
various doses of CNTF to determine which µg/kg ratio is 
most effective in reducing body weight and not inducing any 
apparent adverse effects. Additionally, after stopping 
administration of CNTF, mice will be monitored to determine 
whether they start to regain weight depending on the 
particular dosage. 
 To look at these relationships, knockout mice for 
the Ob gene will be generated as described by Larcher et al. 
(2001) using transfected embryonic stem cells inserted into 
mouse embryos and the NEOR-tk system to delete the Ob 
gene. The resulting ob/ob mice, which will express the 
obesity phenotype due to leptin deficiency, will be injected 
intravenously with different doses of recombinant human 
CNTF or a saline solution (Kelly et al., 2004). A previous 
study by Kelly et al. (2004) demonstrated that CNTF, unlike 
leptin, is able to penetrate the blood-brain barrier, making 
peripheral injections a plausible treatment option.  
Recombinant human CNTF will be produced by 
isolating the Ob gene using PCR amplification, cloning the 
gene product into the bacterial expression plasmid pRSET-
5d that can incorporate larger gene fragments, and inserting 
the plasmid into E. coli cells (Gloaguen et al., 1997). Given 
that CNTF is usually expressed at 100-150 µg/kg in mice, 
injections >150 µg/kg would represent levels that are greater 
than what is normally expressed in mice. Therefore, the 
following amounts of CNTF will be administered to 
experimental groups of mice (n=6): 100µg/kg, 150µg/kg, 
200µg/kg, 250µg/kg, 300µg/kg, 350µg/kg, and 400µg/kg. 
This range allows for the comparison of normal levels of 
CNFT with elevated levels of CNFT. The control group of 
mice (n=4) will be injected in the same fashion with 250 
µg/kg of a saline solution. All mice will be injected once a 
day for 5 weeks. During this time, the weight and body mass 
index of each mouse will be monitored. 
After 5 weeks, the mice will no longer be injected 
with either recombinant human CNTF or the saline solution. 
For an additional 5 weeks, the weight and body mass index 
of each mouse will be monitored to observe whether any 
mice begin to regain weight in relation to the dosage of 
CNTF. 
Based on limited knowledge from prior studies, 
two observational trends are expected: 1) as the amount of 
CNFT increases, the rate at which weight loss occurs will 
increase to a certain extent (at some point this effect will 
plateau because all CNFT receptors will be occupied), and 
2) as the amount of CNFT increases, there is a greater 
likelihood that fever and inflammation will occur. In addition, 
at higher doses of CNFT, the weight loss effects will persist 
over a longer period of time, reducing the need for frequent 
CNTF administration. 
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If no adverse effects are seen between different 
experimental groups in relation to the control group this 
could mean that either the dosage of CNTF is too low to 
produce negative effects or these effects are not manifesting 
themselves physically. This would support studying the 
effect of increased CNTF level on the genomic level. 
 
Examination of the Up Regulation of Genes due to Increased 
Levels of CNFT 
CNTF has a number of different functions in the nervous 
system, with instigation of weight regulation and 
inflammatory response pathways being just two of these 
different effects. Aside from these functions, this protein 
hormone also promotes neurotransmitter synthesis, neurite 
outgrowth in astrocysts, and it initiates other transcriptional 
pathways (Gloaguen et al., 1997; Lambert et al., 2001). 
Therefore, by altering the level of CNTF in the body, a 
number of other pathways could be influenced in the 
process, upsetting the balance of actively transcribed 
proteins and other gene products. In relation to this 
prediction, it would be necessary to examine the change in 
gene expression due an increase in CNTF and identify the 
gene products to determine whether alteration in gene 
expression would be deleterious. 
 To look at the effects of CNTF at the genomic 
level, an experimental group of mice (n=6) will receive daily 
intravenous injections of 300 µg/kg of recombinant human 
CNTF for 3 weeks. This dose of CNTF will be used to 
represent significantly elevated levels of CNFT, while 
avoiding a severe inflammatory response (Kelly et al., 2004). 
Additionally, a control group of mice (n=6) will receive 300 
µg/kg of a saline solution over the same duration. 
 Once a week, over the course of 3 weeks, 
functional magnetic resonance imaging will be completed on 
all mice in the experimental group approximately 30 minutes 
after injection with recombinant human CNTF (Farooqi et al., 
2007). Results from fMRI will allow for identification of 
regions of the brain that are activated in response to CNFT. 
After 3 weeks, both experimental and control mice will be 
sacrificed in compliance with the Institutional Animal Care 
and Use Committee. Based on the brain regions that are 
activated by CNFT, tissue samples will be collected from 
these corresponding regions in both CNTF and saline-
injected mice. The CNFT and saline mice brain cells will be 
cultured separately in vitro following the methods set forth by 
Gloaguen et al. (1997). RNA will be obtained from each cell 
line to generate representative cDNA for the genes 
expressed in each cell type. The cDNA from CNTF-injected 
mice will be fluorescently labeled with Cy3 (green) dye, and 
cDNA from saline-injected mice will be labeled with Cy5 
(red) dye. Microarray analysis will then be completed to 
compare the difference in gene expression between the 
CNTF-injected and saline-injected mice to determine 
influence of increased levels of CNTF (Cell Press, 2005). 
Using this technique, the genes influenced by CNTF can be 
directly identified, and it will be possible to determine 
whether their altered activity can have negative 
consequences. Further studies would be necessary to 
examine the effects of these genes specifically.  
It is expected that there will be a number of genes 
that are either up or down-regulated in the presence of 
higher levels of CNTF, especially in the hypothalamic region 
of the brain (Farooqi et al., 2007). While this approach can 
help to elucidate associated deleterious effects with gene 
expression, it does directly examine the activation of 
signaling pathways. This approach presents only one way in 
which the effects of CNTF can be measured, and it would be 
necessary to examine other aspects of CNTF’s role in the 
brain. 
 
Conclusion 
 
The use of ciliary neurotrophic factor as a potential treatment 
for obesity appears promising because it provides an 
alternative pathway in which weight can be moderated. 
However, the alteration of hormone levels often will not only 
affect one desired pathway but also other processes in 
which it is involved. Results from this study will provide 
further insight into how the dosage of CNTF influences 
weight loss and instigates adverse effects over time, as well 
as how increased levels of CNTF influence the other 
transcriptional pathways. In order to further develop CNTF 
administration as a possible treatment for obesity, a number 
of other factors need to be assessed, especially for long-
term treatment with CNTF. 
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